John E Bartley III (D) K7AAY📎
Giuseppe Michieli''...results suggest that rise of #EG5 & #EG51, as well as #XBB23, infections might not be due to increased capacity ...to enter target cells; ... Of few therapeutic #antibodies still considered useful in clinic, #sotrovimab inhibited both EG.5.1pp & XBB.2.3pp, at least at high concentrations. Finally, we obtained evidence that EG.5.1 evades neutralising antibodies with increased efficiency, at least in context of the immune background of the plasma donors analysed.''
Raj Rajnarayanan 
Excellent and timely data on XBB.1.16 from G2P-Japan!
H/T @SystemsVirology
---
RT @SystemsVirology
Neutralization assay showed that XBB.1.16 is robustly resistant to BA.2 breakthru infection sera (18-fold vs B.1.1) and BA.5 breakthru infection sera (37-fold vs B.1.1). Importantly, XBB.1.16 was sensitive to #sotrovimab, a therapeutic monoclonal antibody (not shown). 5/
https://twitter.com/SystemsVirology/status/1644186063836155905
The Sato Lab (Kei Sato) on Twitter
“Neutralization assay showed that XBB.1.16 is robustly resistant to BA.2 breakthru infection sera (18-fold vs B.1.1) and BA.5 breakthru infection sera (37-fold vs B.1.1). Importantly, XBB.1.16 was sensitive to #sotrovimab, a therapeutic monoclonal antibody (not shown). 5/”
Ms. Opossum (now @ratnegative)The "profound and rapid" selection pressure induced by the mAbs is partly to blame; for example, 33.3% of BA.1 and 0% of BA.2 infected patients developed mutations when treated with #sotrovimab. The drug neutralizes the former more efficiently than it does the latter.
simonthelwallNew pre-print out by my team.
Mutations present in BA.2 spike, combined with in vitro data raised the possibility that Sotrovimab would have reduced effectiveness against #sars-cov-2. Our results indicate that there was no increased risk of hospital admission for BA.2 compared to BA.1, among people treated with #sotrovimab
https://www.medrxiv.org/content/10.1101/2022.10.21.22281171v1.full.pdf
AltreconomiaBrevetti e pillole amare: l’Ue continua a difendere Big Pharma, non solo sui vaccini https://altreconomia.it/brevetti-e-pillole-amare-lue-continua-a-difendere-big-pharma-non-solo-sui-vaccini/ #CorporateEuropeObservatory #immunosoppressore #Approfondimento #astrazeneca #monoclonali #Tixagevimab #Tocilizumab #Sotrovimab #anticorpi #covid-19 #pfizer #covid #Merck #Roche #GSK
Brevetti e pillole amare: l'Ue continua a difendere Big Pharma, non solo sui vaccini
Dopo aver negato ai Paesi a basso reddito un accesso equo ai vaccini, l’Unione europea è pronta a fare lo stesso con i medicinali per il trattamento del Covid-19, privilegiando gli interessi di Pfizer, Merck, Roche, AstraZeneca e GSK e tagliando fuori milioni di persone. La denuncia del Corporate europe observatory